LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30-June 3, 2008. Data will be presented from studies highlighting the potential utility of ABRAXANE (ABI-007) in combination with the targeted agents bevacizumab and trastuzumab, and other chemotherapeutic agents, for neoadjuvant and first-line treatment of metastatic breast cancer.
